Host: The Japanese Society of Toxicology
“Read-across” (RAx), a method of estimating the toxicity based on the structural similarity, is attracting attention as a technology of toxicity prediction that utilizes existing data on safety. In order to refine the accuracy of RAx, it is necessary to accurately reflect the rules between structure and toxicity by considering Adverse Outcome Pathways. We are working on standardization of the RAx strategy by accumulating case studies, and the precise prediction is expected by the Omics analysis, bioassay for key events and pharmacokinetics data. In the lecture, I’d like to introduce the strategy in our company regarding the non-animal testing to realize precise quantitative risk assessment.
